RLMD
Relmada Therapeutics, Inc. · Healthcare
Director Paul Edward Kelly sold $300K of Relmada Therapeutics, Inc.
Sold$300,395
$30.04Price
10,000Shares
−5%Stake
What RLMD did after the filing
- The stock from Tue, Apr 5 close, $29.82
- −27.2%
- S&P 500, same days
- −13.1%
Measured over 30 trading days, to the May 18 close.
Traded Mon, Apr 4. Filed Tue, Apr 5, 1:34 PM ET, during the session. Returns use the Apr 5 close and the May 18 close. Not investment advice.